Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pattern in GLP-1 CNS efficacy. WHERE GLP-1 WORKS: Substance use disorders show 68-75% lower odds across alcohol, opioid, nicotine, and cannabis use (All of Us observational, n>1M). Alcohol use disorder RCT demonstrated 41%
GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits,
Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
As of Q1 2026, no formal American Psychiatric Association clinical practice guideline exists for GLP-1 receptor agonist use in psychiatric populations. Instead, the Psychopharmacology Institute — a widely used CME platform for psychiatrists — published structured clinical guidance as part of their q
Semaglutide reduces effort-cost sensitivity in major depressive disorder through reward circuit engagement, not cognitive enhancement
In a 16-week double-blind RCT (n=72), oral semaglutide 14mg significantly reduced sensitivity to effort cost in effort-based decision-making tasks (β = -1.737; P = .03) while showing no effect on executive function (adjusted Z score difference: 0.32; 95% CI: -0.92 to 1.58; p=0.60). This dissociation
GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
This systematic review categorizes anhedonia as a 'potential adverse outcome' but notes that 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse.' Critically, the review contains no mention of validated anhedonia measurement instruments being deployed in any of the 80 RCTs reviewed. The Snait
Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
This systematic review of 80 RCTs (107,860 participants) plus large cohort studies explicitly identifies the complete absence of human dose-response data on GLP-1 psychiatric effects as a critical evidence gap. The review notes that preclinical evidence shows 'GLP-1 signaling exerts both anxiogenic
GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic
Natural GLP-1 is phasic: it spikes after meals and degrades within 1-2 minutes due to its endogenous half-life. Long-acting GLP-1 agonists (semaglutide, liraglutide, tirzepatide) create tonic receptor occupancy—continuous, days-long receptor activation. GLP-1 receptors are densely distributed in psy
Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison
A Swedish national registry study published in Lancet Psychiatry (March 2026) used within-individual stratified Cox models to compare psychiatric outcomes during periods when the same person was ON versus OFF semaglutide. This design eliminates all time-invariant confounding including baseline psych
Primary care prescribers of GLP-1s at therapeutic weight-loss doses lack psychiatric competency to monitor for CNS effects, creating structural risk of anhedonia in patients without psychiatric support
GLP-1 receptors are densely distributed in VTA, nucleus accumbens, insula, and prefrontal cortex—psychiatric-relevant brain circuits. The drugs function as dopaminergic modulators, not just metabolic agents. However, psychiatrists are managing patients prescribed GLP-1s by primary care/endocrinology
Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
The apparent divergence in GLP-1 psychiatric safety evidence—matched cohort studies showing 195% increased MDD risk versus RCTs and within-individual studies showing protective or neutral effects—is resolved by understanding confounding by indication. The Swedish Lancet Psychiatry study (March 2026)
GLP-1 eating disorder screening protocol combining SCOFF questionnaire, recent ED history review, and compensatory behavior assessment is recommended for pre-treatment risk stratification
The systematic review identifies a specific pre-treatment screening protocol for GLP-1 receptor agonist prescribing: (1) SCOFF questionnaire administration, (2) recent ED history review, (3) assessment for compensatory behaviors, and (4) weight-suppression history evaluation. This represents a clini
GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population
The ISPOR study analyzed over 60,000 GLP-1 users and found cumulative eating disorder incidence of 1.275% across all users, with a critical stratification: GLP-1 users with prior mental health conditions had MORE THAN DOUBLE the eating disorder risk compared to GLP-1 users without mental health hist
GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
Multiple clinicians quoted in NBC News describe a progression pattern: beneficial appetite suppression → pathological restriction → 'atypical anorexia nervosa' presentation. The proposed mechanism is that the brain 'may interpret dramatic sudden weight loss as starvation, triggering obsessive food t
GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology
Dr. Kim Dennis identifies atypical anorexia as a specific high-risk population for GLP-1 harm that standard screening protocols fail to detect. Atypical anorexia nervosa is characterized by meeting full diagnostic criteria for anorexia nervosa—including restrictive eating patterns, fear of weight ga
GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
Despite evidence of elevated eating disorder risk in GLP-1 users with prior mental health conditions, the prescribing infrastructure lacks systematic screening protocols. Timmerman Report documents that: (1) no standard protocol for eating disorder screening before prescribing exists, (2) no safety
GLP-1 harm risk is mediated by cultural weight stigma and pressure rather than pharmacological properties alone
Robyn Pashby articulates the dual-truth framework: 'GLP-1s are legitimate evidence-based treatments for obesity, but they also sit inside our culture, which has intense weight pressure, weight stigma and eating disorder risk.' This positions harm not as inherent to the drug but as emergent from the
GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment
This case report documents an adolescent prescribed semaglutide who developed severe atypical anorexia nervosa with life-threatening cardiac complications (bradycardia 38 bpm, pericardial effusion) within 6 months. The critical finding is that 18 months of pre-prescription restrictive behaviors—incr
Expert divergence on GLP-1 eating disorder causality reflects fundamental evidence gap between clinical pattern recognition and epidemiological confirmation
Dr. Aaron Keshen reports EDs developing 'in people who take drugs as prescribed' supporting direct causality, while Dr. Anjali Pandit states 'not seeing this frequently' suggesting prescriber screening matters significantly. This is not a scientific debate about interpretation of shared data — it's
Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
The 'Ozempic personality' phenomenon reveals a narrative framing problem: patients widely report 'food noise quiet' as a positive liberation from obsessive food thoughts, while the same dopaminergic suppression mechanism causes reduced interest in social activities, sex, music, and pleasure generall
GLP-1-induced GI side effects may reinforce pre-existing purging cycles but no clinical evidence supports de novo eating disorder induction in patients without behavioral vulnerability
This systematic review provides the strongest current evidence synthesis on GLP-1 receptor agonists and eating disorder risk. The review explicitly states: 'To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN.' This is a definitive closure of the de novo causation hypothe
Semaglutide silences AgRP starvation-protection neurons, amplifying the relative importance of behavioral and social factors in determining eating disorder risk
Northwestern researchers identified a 'double whammy' mechanism for semaglutide's appetite suppression: it both signals fullness through standard GLP-1R agonism AND silences AgRP neurons that normally activate during negative energy balance to protect against starvation. Dr. Beutler describes AgRP n
GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addic
GLP-1 GI side effects trigger purging behaviors in vulnerable populations creating direct pharmacological harm pathway not just psychological reinforcement
ANAD documents that GLP-1 receptor agonists' most common side effects—nausea, vomiting, diarrhea, and gastroparesis—'can trigger or worsen purging behaviors' in individuals with eating disorder histories or vulnerabilities. This is not an indirect psychological effect but a direct pharmacological pa
GLP-1 eating disorder risk is subtype-specific: protective for binge eating disorder but potentially harmful for restrictive eating disorders through the same appetite suppression mechanism
This review establishes that GLP-1 receptor agonists create opposing clinical outcomes across eating disorder subtypes through a single pharmacological mechanism. For binge eating disorder (BED), GLP-1 RAs reduce binge episodes by modulating mesolimbic dopamine circuits that drive reward-based eatin
WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
The WHO issued a global guideline on December 1, 2025, recommending GLP-1 receptor agonists (semaglutide and two other agents) for long-term obesity treatment in adults. The guideline news release identifies only one explicit population exclusion: pregnant women. No eating disorder contraindications
Page 3 of 13